Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    97
    ...
ATC Name B/G Ingredients Dosage Form Price
R03DA04 THEODEX G Theophylline - 80mg/15ml 80mg/15ml Elixir 156,142 L.L
A02BC01 OMEPRAL G Omeprazole - 10mg 10mg Powder for suspension 890,776 L.L
A07EC02 SALCROZINE G Mesalazine - 1g 1g Tablet, gastroresistant 4,073,187 L.L
A10BK01 DIVINUS G Dapagliflozin propanediol - 10mg 10mg Tablet, film coated 2,316,784 L.L
B05CX01 DEXTROSE 10% INJECTION, USP G Glucose - 10% 10% Injectable solution 283,847 L.L
C02CA04 UNIPROST G Doxazosin - 4mg 4mg Tablet 452,875 L.L
C10AA05 TOVAST G Atorvastatin (calcium) - 10mg 10mg Tablet, film coated 1,127,484 L.L
D07AC13 ELICA G Mometasone furoate micronized - 1mg/g 0.1% Ointment 399,121 L.L
J01CA04 OSPAMOX G Amoxicillin (trihydrate) - 250mg/5ml 250mg/5ml Powder for suspension 223,078 L.L
J05AF10 ENTECAVIR BIOGARAN G Entecavir - 1mg 1mg Tablet, coated 19,080,319 L.L
L01CD04 CABOTAX G Cabazitaxel - 60mg/1.5ml 60mg/1.5ml Injectable concentrated powder for solution+diluent 45,371,506 L.L
L01XA03 OXALIPLATINE VIATRIS 5MG/ML G Oxaliplatin - 50mg 50mg Injectable powder for solution 4,428,565 L.L
L04AX04 LENALIDOMIDE STRAGEN G Lenalidomide - 5mg 5mg Capsule 33,314,752 L.L
N05AH04 JOSWE QUZAL 25 G Quetiapine - 25mg 25mg Tablet 258,018 L.L
N06DA02 DONECEPT 5 G Donepezil HCl - 5mg 5mg Tablet, film coated 1,970,969 L.L
R03DA05 AMINOPHYLLINE RENAUDIN G Aminophylline - 250mg/10ml 2.5% Injectable solution 739,113 L.L
S01CA01 LEVIOSA G Levofloxacin - 5mg/ml, Dexamethasone - 1mg/ml Drops solution 1,427,161 L.L
A02BC02 GASTROPAN G Pantoprazole (sodium) - 40mg 40mg Tablet, enteric coated 1,104,639 L.L
A10BK01 ZYGLOR 10 G Dapagliflozin - 10mg 10mg Tablet, film coated 2,039,953 L.L
B05CX01 SOLUFLEX DEXTROSE 10% INJECTION, USP G Glucose - 10% 10% Injectable solution 219,493 L.L
C02CA06 TACHYBEN G Urapidil - 25mg/5ml 25mg/5ml Injectable solution 1,439,255 L.L
C09BA05 TRILTEC PLUS G Ramipril - 10mg, Hydrochlorothiazide - 12.5mg Tablet 2,243,577 L.L
C10AA05 TULIP G Atorvastatin (calcium) - 10mg 10mg Tablet, film coated 899,031 L.L
J01CA04 AMOXYDIL G Amoxicillin (trihydrate) - 500mg/5ml 500mg/5ml Powder for suspension 218,854 L.L
J05AF10 ENTRILIV G Entecavir - 1mg 1mg Tablet, film coated 11,475,203 L.L
L01XA03 OXALIPLATINO PHARMINICIO G Oxaliplatin - 50mg 50mg Injectable lyophilised powder for solution 2,956,454 L.L
L04AX04 LENOMA G Lenalidomide - 5mg 5mg Capsule, hard 68,908,116 L.L
N02BE51 A.B.C.-COLD G Paracetamol - 500mg, Chlorphenamine maleate - 4mg, Phenylephrine HCl - 5mg Tablet, film coated 534,977 L.L
N05AH04 JOSWE QUZAL 25 G Quetiapine - 25mg 25mg Tablet 490,503 L.L
N06DA02 DONEPEZIL ARROW G Donepezil HCl - 5mg 5mg Tablet, film coated 1,365,344 L.L
    ...
    97
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026